A mechanistic model of amyloid beta production, degradation, and distribution was constructed for mouse, monkey, and human, calibrated and externally verified across multiple datasets. Simulations of single-dose avagacestat treatment demonstrate that the Ab 42 brain inhibition may exceed that in cerebrospinal fluid (CSF). The dose that achieves 50% CSF Ab 40 inhibition for humans (both healthy and with Alzheimer's disease (AD)) is about 1 mpk, one order of magnitude lower than for mouse (10 mpk), mainly because of differences in pharmacokinetics. The predicted maximal percent of brain Ab 42 inhibition after single-dose avagacestat is higher for AD subjects (about 60%) than for healthy individuals (about 45%). The probability of achieving a normal physiological level for Ab 42 in brain (1 nM) during multiple avagacestat dosing can be increased by using a dosing regimen that achieves higher exposure. The proposed model allows prediction of brain pharmacodynamics for different species given differing dosing regimens.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? þ Multiple AD treatments are developed targeting production of amyloid b. CSF and plasma Ab are the main PD biomarkers in humans, so for understanding of brain PD, preclinical models are extensively used.
WHAT QUESTION DOES THIS STUDY ADDRESS?
þ The questions this study address are 1) whether a mechanistic translational model can allow for prediction of short-term GSI pharmacodynamics in humans, and 2) what inhibition levels can be achieved in human brain, given the information on the system and drug PK.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE þ The mechanistic model allows comprehensive comparison of different species revealing the difference in Ab transport and production. Different sensitivities of brain and BIF Ab to drug AUC requires a specific schedule to normalize brain Ab. HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS? þ Our model allows for more accurate translation of preclinical results to clinical data and optimization of therapeutic regimen. It provides a link between measured biomarkers and unobservable brain concentrations for estimation of the real drug effect on amyloid toxicity.
Cognitive decline in Alzheimer's disease (AD) is usually preceded by the accumulation of the pathologic amyloid beta (Ab) protein in the brain. Both insoluble and soluble forms of Ab may be neurotoxic. In familial forms of AD, genetic mutations may be responsible for modified (increased or decreased) Ab turnover. 1 Other hypothesized mechanisms (e.g., tau pathology, inflammatory response, vascular and metabolic dysfunction 2, 3 ) for AD etiology are considered, but Ab-related toxicity participates in most of them. The Ab hypothesis is being tested in multiple clinical trials evaluating drugs that can alter Ab kinetics in humans. Passive immunotherapy against Ab is tested in trials of bapineuzumab by Elan, 4 Solaneuzumab by Eli Lilly, and crenezumab and gantenerumab by Roche/Genetech (Clinicaltrials.gov). Amyloid production inhibition efficacy is now tested for verubecestat by Merck, AZD-3293 by Astra Zeneca, and JNU-54861911 by Janssen. The influence on amyloid clearance pathways is tested for retinoid receptor agonists such as acitretin by Actavis/Allergan, and bexarotene by Ligand Pharmaceuticals. Gamma-secretase inhibitors (GSI) avagacestat by BMS and semagacestat by Eli Lilly have also been tested and have shown no success.
Ab is produced primarily in the endosome and plasma membrane of neurons 5 and to a lesser extent in cells of other tissues. 6, 7 Given the proximity of cerebrospinal fluid (CSF) to brain, for clinical trial purposes the change in the CSF Ab level has been used as an indicator for brain Ab modulation upon therapeutic intervention that targets brain Ab production or clearance. Plasma Ab has been monitored in early-stage clinical trials as a quick endpoint for assessment of peripheral pharmacological activity. However, the relationship between brain, CSF, and plasma Ab is not straightforward, and peripheral pharmacological activity does not necessarily translate into central pharmacological activity. Depending on the class of therapeutic, different patterns of Ab kinetics, in plasma and CSF, have been reported. A pronounced rebound in plasma Ab concentrations was observed for GSI, avagacestat, and semagacestat, in human 8, 9 and in mouse, 10 as well as in CSF for avagacestat doses 15-50 mg in humans 11 and 30 mpk of 1 semagacestat and GSI-953 in wildtype mouse. 10 No rebound in the brain Ab concentrations was observed in the wildtype or transgenic mouse models 10 for avagacestat, semagacestat, or GSI-953 treatment. 10 The quantitative understanding of the Ab trafficking between brain, CSF, and plasma is of great importance for development of new anti-AD therapy and AD diagnostics.
The majority of experimental data on Ab distribution kinetics were obtained from in vivo mouse models 12, 13 by monitoring radiolabeled Ab concentrations in plasma, CSF, and brain. Additional preclinical models (mouse, monkey) have also been used to study Ab responses in brain, CSF, and plasma following administration of Ab-modulating therapeutics in drug discovery. 10, 14 Similar studies have also been conducted in healthy volunteers and AD patients to understand Ab kinetics with or without pharmacological intervention. 9, 15 Despite the availability of these data, there have been limited efforts in developing a quantitative understanding of Ab kinetics across species.
Three types of mathematical models on Ab kinetics exist in the literature, all with limited utility in providing a quantitative, holistic, cross-species understanding. The first type is the semimechanistic pharmacokinetic/pharmacodynamic (PK/ PD) modeling that focuses on characterizing the pharmacodynamics of Ab-modulating agents 10, 16, 17 in preclinical and clinical experiments. They usually do not include such details as description of c-secretase as an enzyme catalyzed process and Ab transport across the blood-brain barrier (BBB) and blood-CSF barrier (BCSFB). The second type of model (e.g. Ref. 18) , describes the accumulation and distribution of Ab in the brain, CSF, and plasma, throughout the course of AD treatment, but calibrated against a limited amount of data. The third type is focused on analyzing stable isotope labeling kinetic (SILK) data, 19 limited by the scope of data without any extrapolation to the brain compartment.
To further the understanding of Ab kinetics across species, and more important, to create a tool to enable drug discovery and development in AD, we present a translational mechanistic model of Ab synthesis, degradation, and distribution.
METHODS
The model describes Ab forms (Ab 40(42) , labeled Ab 40(42) ) in brain cells (BC), brain interstitial fluid (BIF), CSF, plasma (PL), and other tissues (OT), and C99 in BC, BIF, and OT ( Figure 1a) . Concentration of species changes due to synthesis, distribution, and degradation. The description (model structure, rate equations) of the other amyloid forms (Ab 42 , labeled Ab 40 , labeled Ab 42 ) is identical to that for Ab 40 (Figure 1a ) in the full model (Figure 1b) . The final model consisted of 26 ODEs for Ab and C99, ODEs and explicit function for PK of GSIs, 70 rate laws, and 70 parameters (Supplement A, Table S1 ). The description of different experimental conditions (labeled Ab injection or labeled leucine infusion), specific initial values, or input of additional rates is detailed in Supplement B.
The model has the same structure (variables, compartments, and rate equations) for all the species (mouse, monkey, and human).
Mechanisms of amyloid aggregation in BIF are not described, so this model is not applicable for longerduration simulations and the mechanistic description of disease progression. The pathological AD state is treated as steady state with altered values of Ab production 20, 21 and clearance in brain (see details in Supplement A).
Interspecies scaling Interspecies translation of model parameters was performed using allometric scaling (a generic equation as below):
where P and P 0 are reaction rate constants of species with body weight BW and BW 0 , respectively, and n is the scaling exponent. The allometric scaling alone may not allow for satisfactory translation from rodents to primates, so additional scaling coefficients for groups of processes were incorporated (Supplement A).
Model calibration and evaluation
The model calibration steps across different data types ( 40 data in brain and CSF from an avagacestat dataset. The main goal was to describe human data as accurately as possible, so a human dataset (which is rich enough) was used for translation from rodents to primates: steady-state concentrations, SILK data, and GSI PD were fitted by scaling factors for Ab production and distribution (Table S2) ; then a monkey dataset (steady-state values, SILK data) was used for external verification without scaling factor refitting. The semagacestat dataset 24 was chosen for calibration among GSI data, as it was complemented by SILK kinetic data, while avagacestat human PD data were used for external verification.
Description of PK of avagacestat and semagacestat
The PK time courses that drove the systems model for avagacestat and semagacestat were implemented using compartmental PK modeling or explicit functions where appropriate (see Supplement B) for reproduction of observed PK data. Values of IC 50 measured in vitro 10 were used in equations for c-secretase inhibition (Supplement A,B). Due to lack of the brain PK data, we assumed for simplicity brain PK profiles analogous to plasma profiles with correction for brain penetration coefficients. A full description of experimental facts and model assumptions, ODE system, rate laws, values of model parameters, and experimental data used for model calibration and validation is given in the Supplementary Materials. 
Simulation design
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Karelina et al. Different variants of BW-independent scaling parameters of synthesis, enzymatic, and transport reactions were tested. Satisfactory results were obtained by fitting 11 parameters for interspecies scaling (Table S2 of Supplement) and four parameters for scaling from healthy to AD state as specified in "Methods" ( Table 2 ). Five parameters ( Table 2 ) describe scaling from mouse to human and thus illustrate the magnitude of difference in Ab synthesis between species.
RESULTS
Model calibration and verification
After translation to primates, the model was externally verified on monkey data: body weight based allometric scaling alone was sufficient to describe the data (Figure 3a , Supplemental Figure B11 ).
Description of human GSI data. GSI treatment prediction performance was verified comparing the clinical avagacestat single dose data for healthy individuals (Figure 3b ) with simulations of treatment at an IC 50 value measured in Table 1 Description of stages of model construction and external verification
Step # Description of step Type of data used in the step
Number of points
Parameter identification fitting EV* vitro, and measured PBPK parameters (Table S2) . Data for Ab PD during GSI treatment often demonstrate strong fluctuations, which may be explained partially by diurnal Ab oscillations, which were not accounted for in the model. However, the amplitude of inhibition (minimum of PD curve) falls within the 95% prediction band for each of measured quantities, except for Ab 42 inhibition, and exceeds the accuracy of prediction achieved in the work of Niva et al. 17 We conclude that this model satisfactorily predicts inhibition.
Insights from simulations and implications for drug discovery and development CSF and brain Ab 40 inhibition in human vs. mouse. We simulated the Ab response to single-dose avagacestat administration in the mouse and human (analogous to those presented in Figures 2b, 3b) to study the dependence of PD characteristics on dose and area under the curve (AUC). Model predictions were compared (Figure 4) to data used for fitting (mouse Ab 40 data) and The model adequately characterized the dose dependence for the "amplitude of Ab 40 inhibition" in CSF and brain (Figure 4a) , suggesting that 1) maximal inhibition (I max ) of avagacestat for brain Ab 40 is about 50% for healthy subjects and 60% for AD subjects; 2) avagacestat dosages, leading to the same magnitude of CSF Ab 40 decrease in mouse and human, are different; 3) although doses allowing to reach half-maximal inhibition at the peak (ID 50 ) for humans and mouse are substantially different, the model satisfactorily predicts the magnitude of human CSF Ab 40 inhibition in points not used for fitting; and 4) brain inhibition is lower than CSF for high dosages for all species.
Extrapolation from Ab 40 to Ab 42 pharmacodynamics. The Ab 42 PD data were not used for calibration of the model. The model simulations of the Ab 42 compartments tend to underestimate CSF Ab 42 inhibition (human data, Figure 4a ) and overestimate brain inhibition (mouse data). It appears that Ab 42 was not predicted satisfactorily based on Ab 40 data fitting even for the same species (mouse).
Exploration of exposure-effect relationships. The resulting drug exposures corresponding to the observed single-dose PD effects were similar for all species for brain Ab 40 inhibition (Figure 4b ). The differences in ID 50 (Figure 4a ) between mouse and human are driven in part by species-related PK properties. The large difference in CSF Ab 40 responses, as captured by area under the effect curves (AUEC) (Figure 4b ), may result from the different contributions of brain production to CSF concentration among species (Supplemental Figure C1 ). The brain Ab pool is completely determined by brain production, while CSF and plasma Ab may depend on production in other tissues (see details in Supplement C). 26 This conforms to the fact that the steady-state brain concentrations of Ab 42 in healthy humans and mice are below 1 nM, while for AD subjects Ab 42 exceeds 1 nM (Figures 2a, 3a) . We have specified in our simulations that 1 nM in brain cells would be the reference level for toxicity. Semagacestat and avagacestat demonstrate similar dose dependence for BIF Ab inhibition in AD subjects during 3 days (Figure 5a) . A significant difference between drug efficacy (semagacestat vs. avagacestat) is observed for BC inhibition (Figure 5a, bottom) , with the central tendency of returning BC Ab 42 concentrations to physiological values. The 95% prediction confidence band for the brain Ab 42 inhibition by semagacestat reaches the region of safe concentration only at the highest doses simulated (Figure 5a ). For avagacestat, the median reaches 1 nM corresponding to $80% inhibition of Ab 42 concentration from about 8 nM at steady state level in brain for AD subjects (Figure 5b) .
Efficacy of GSI on
Analysis of different GSI therapeutic regimens. Brain AUEC is more sensitive to plasma AUC than CSF AUEC at moderate doses (Figure 4) according to model predictions. This is explained through the model given the different dynamics of inhibition: Brain Ab inhibition follows Ab inhibition in CSF with some delay (Supplemental Figure C2) , and both of them are delayed with respect to maximal drug concentration and maximal plasma inhibition. An optimized dosing regimen could lead to a potential therapeutic benefit due to higher AUC. We simulated 3 days of avagacestat treatment (analogous to previous section) with different dosing regimens. All simulated regimens with multiple daily dosing, even with a lower daily dose, provide better brain pharmacodynamics than the single dosing regimen (Figure 5b) . The forecasted brain cell Ab concentrations fell below 1 nM on the third day of simulated therapy. Moreover, each regimen provided enough safety, as the minimal BIF concentration did not fall below the normal range of values. A q.d. regimen has the lowest AUC (Figure 5c ) even when compared with lower total daily dosing regimens. Higher AUC lead to higher maximal BC amyloid inhibition, but not maximal BIF inhibition.
DISCUSSION
The purpose of this study was 1) to apply the model to evaluate contributions of different sources of Ab (synthesis in brain and other tissues) to its level in brain cells, brain interstitial fluid, CSF, and plasma; 2) to explore the translation of GSI mechanistic dynamics across mouse, monkey, and human species; and 3) to identify GSI administration regimens that would return Ab to normal human (non-AD) levels.
The developed model satisfactorily describes the kinetics of Ab distribution and steady-state levels in mouse, monkey, and human (healthy subjects and AD patients).
Model calibration efforts confirmed that conventional allometric scaling, of reaction rates, was not sufficient to translate the model from mouse to humans, reflecting that significant differences exist between these species that may not be explained solely by body weight. They relate not only to the production of Ab, but also to its degradation and transport. Dissimilarity of these processes between species was found in three parameters other than for Ab production. Bulk flow from BIF to CSF in humans differs by an order of magnitude from the value calculated by allometric scaling, reflecting possible involvement of other mechanisms in brain Ab fluxes. Plasma-CSF Ab exchange is greater in humans according to the model, suggesting possible differences in BCSFB architecture across species. In contrast to mouse-human translation, body weight-based allometric scaling is sufficient for the translation between human and monkey, therefore the monkey may be a better preclinical in vivo model for biomarker translation.
The Ab 42 /Ab 40 ratio is higher in human brain than in plasma and CSF (see Figure 3 with illustration of data from different references [27] [28] [29] [30] [31] ). Moreover, the CSF Ab 40 level is much higher in humans than in mouse, while brain concentrations are similar. Plasma Ab 40 Table 2 ). The possibility that the higher level of CSF Ab in humans is due to lower degradation seems unlikely, as the model correctly describes Ab clearance after GSI administration. Many minor differences may exist between mouse and humans, but we have chosen only a few parameters identifiable given the dataset. According to the same reasoning, the AD state may be a result of slight changes in an extended set of processes, but here it was described by changing production and aggregation addition only ( Table 2) . This is in line with an increase of b-secretase activity 32 and contribution of aggregation into equilibrium between soluble and insoluble forms in BIF. As there is no dynamic data for GSI in AD, it is not clear whether an increased BC concentration in AD is due to increased production or failure of intracellular transport or degradation, so calibration only on baseline data allows for determining only some effective parameters. This is an important limitation, which should further be eliminated by extension of calibration on new PD data. 33 GSI treatment maximal effect is reproduced by the model, but some dynamic properties were not accurately described. The overshoot for human Ab plasma concentration is underestimated for semagacestat (Supplement Figure B9) and . Symbols correspond to measured data: circles correspond to data used for fitting, 10 crosses correspond to data used for validation of human CSF predictions, 8, 11, 17, 50 and mouse brain Ab 42. 10 low doses of avagacestat ( Figure 3b ) and overestimated for higher avagacestat doses (Figure 3b) . Model predictions for CSF Ab show a similar pattern but do not completely follow the data. Problems with the PD description are observed in the mouse also (Figure 2b) : both brain and CSF curves predicted by the model lag behind the measured points during the decline phase. It can be assumed that the description of distribution between BIF and brain cells is simplified: exchange between these compartments is carried out by different mechanisms, including endocytosis and exocytosis, 34, 35 while there is one hypothetical carrier in our model responsible for transport. Another possible explanation is that drug IC 50 values measured in vitro may not reflect the physiological situation.
Comparison of the inhibition amplitudes in different species ( Figure 4) leads us to the conclusion that CSF Ab 40 has approximately the same biomarker capacity for humans and mouse, slightly overestimating brain inhibition (for AD subjects CSF 75% Ab 40 inhibition corresponds to $60% brain Ab 40 inhibition for avagacestat dose of 10 mpk). Healthy subject CSF data underestimate the potential CSF inhibition level for AD subjects. Avagacestat doses of $2 mpk would lead to about 55% inhibition of Ab 40 in CSF of healthy controls, while about 65% inhibition in CSF and 50% inhibition in brain are predicted for AD subjects. Clinically tested dosages (below 150 mg avagacestat for AD 36 ) do not allow achieving a normal concentration (Figure 5a ), but may lead to a BIF Ab concentration decrease below the physiological level.
Ab 42 pharmacodynamics for one GSI (e.g., avagacestat) cannot be predicted based on the PD data for Ab 40 or Ab 42 from another GSI (e.g., semagacestat) directly (Figure 3 ) even for the same species (mouse or human). In our model GSI acts on the total secretase rate, and so Ab pharmacodynamics is determined by such system properties as proportions of Ab 40/42 synthesis in different compartments and clearance (distribution). To describe higher inhibition of Ab 42 we should suppose a specific mechanism leading to changes in the proportion of Ab 40/42 production: drug interaction with presenilin 37 or detailed analysis of drug action in different intracellular compartments. Analysis of AUEC and AUC (Figure 4b ) have shown that even the exposureresponse relationship difference between species will not be explained by PK properties only and, moreover, the difference in the brain Ab 42 inhibition between AD and healthy individuals should be expected.
A difference in the exposure-response relationship between brain and CSF ( Figure 4 , Supplement Figure C2 ) is expected to be due to the different Ab half-lives in brain and plasma and different contributions of plasma amyloid to brain and CSF (Supplement Figure C1) . The overshoots of CSF Ab concentration, predicted for all species, may originate simply from c-secretase substrate accumulation in our model, as we do not consider more complex enzymology. 38 It is similar in general to the mechanism proposed previously, 39 assuming overwhelmed a-secretase processing by C99 and increased APP pool. Slight overshoot in the brain is observed only for healthy subjects probably because of the different relationship between synthesis and degradation of Ab ( Table 2, Table S2 ).
Soluble nonfibrillar Ab has been demonstrated to be more toxic to neurons than the aggregated form. 26, 40, 41 The model presented here allows for direct comparison of the concentrations of soluble amyloid species, forecast from the model, and the proposed toxicity thresholds as defined by in vitro studies in such inaccessible compartments as BIF and even brain cells. It could facilitate understanding the reasons for the failure of many GSI clinical trials. PD simulations for a long time require: 1) more accurate PK description, as differences between PK on days 1 and 7 have been shown 11 ; 2) description of amyloid aggregation and accumulation processes; 3) disease progression description. As all of these considerations are out of the scope of this analysis, we simulated PD for only 3 days of treatment and assumed that it will give a rough estimate of the results of trials, which can later be compared with the results of an extended model. Achieving brain Ab levels corresponding to normal concentrations (Figure 5a ) requires very high avagacestat dosages conjugated with a risk of decrease below an optimal BIF level of Ab. This effect, if it exists in vivo, would be independent of the mechanism of production inhibition (BACE or GS inhibition), as it is related to Ab level decrease, but not to other pathways, e.g., Notch signaling inhibition, observed for semagacestat, 42 or substrate accumulation. 43 Saturation of effect at avagacetat dosages higher than 5,000 mg may be due to a decrease in bioavailability for higher dosages and absorption saturation assumed in the model (Supplement B.1). Differences between brain efficacy of semagacestat vs. avagacestat are due to the distinct plasma-brain penetration coefficients (0.05 for semagacestat vs. 4.35 for avagacestat 10 ) and different PK profiles: long decay (Figure 2(b) , Supplement) together with high brain penetration and low IC 50 of avagacestat allows retaining substantial brain inhibition for a much longer period of time. Our simulations have shown the importance of higher AUC for brain inhibition, but not for BIF inhibition (Figures 4, 5) , suggesting that PK properties are significant for brain PD.
The reason for the different dynamics in BIF and BC may be the exchange between BC and BIF: in the model, the equilibrium constant between rates of uptake and release was fitted to 10, in line with observed extensive uptake, 44 which leads to faster depletion of BIF Ab. Both brain and BIF concentrations depend mainly on brain production, and thus, the only way to provide a positive difference in BC and BIF PD, besides the specific dosing regimens, would be the development of a compound with a different intraand extracellular IC 50 or a drug influencing intra-and extraneuronal amyloid transport. Compounds should have a lower clearance rate to be able to retain high drug plasma concentrations for a longer period of time.
CONCLUSION
The proposed model can be considered a framework for exploration of the amyloid system, translating between species, hypothesis generation, and understanding therapeutic options targeting this system. Key problems in construction of this model are the choice of datasets that are optimal for model fitting and external verification, and handling multiple datasets and analyzing accuracy of predictions.
In the accompanying article, we extend our Ab distribution model in such way as to take into account Ab 40 and Ab 42 aggregation with longitudinal time effects to describe AD progression over the decades. 
